Cinpathogen Research Indicates Significant Differences in the Prevalence of MDS Between China and the West.

Share Article

Speaking at the Benzene 2009 Symposium, Dr. Richard Irons, CEO of Cinpathogen, Inc., announced significant differences in the prevalence of myelodysplastic syndrome (MDS) subtypes between China and the West. The findings indicate a need for different therapeutic strategies to treat the disease in China.

These results may benefit patients currently in treatment and assist researchers working on new therapies.

Speaking at the Benzene 2009 Symposium, Dr. Richard Irons, CEO of Cinpathogen, Inc., announced significant differences in the prevalence of myelodysplastic syndrome (MDS) subtypes between China and the West. The findings indicate a need for different therapeutic strategies to treat the disease in China.

Dr. Irons' presentation summarized a portion of the findings from the Shanghai Health Study. As part of the study, Cinpathogen researchers diagnosed and analyzed 649 new cases of MDS in Shanghai over a four year period. With that number of cases, it's believed they have completed the largest individual study of MDS anywhere in the world, to date.

Key findings include:

  •     The median age for MDS development in China is 15 years younger than in the West
  •     MDS associated with benzene exposure appears to present differently than unexposed MDS cases.

"There is immense satisfaction in knowing we, along with our collaborators, have answered questions that have been on the table for decades," said Dr. Irons. "These results may benefit patients currently in treatment and assist researchers working on new therapies."

Cinpathogen recently completed its portion of the Shanghai Health Study, an eight and a half year research project to study the prevalence of hematopoietic and lymphoid diseases in Shanghai. Particular attention was given to the role of benzene in these diseases.

Participating institutions, orchestrated by Dr. Richard Irons, Cinpathogen CEO, include Fudan University, the University of Colorado, the Shanghai Hematology Society, and the Shanghai Pathology Society. The project was funded by the Benzene Health Research Consortium from January 2001 to Sept. 2009.

Cinpathogen, a leading biomedical research and consulting firm in Shanghai, operates the Fudan-Cinpathogen Clinical and Molecular Research Center providing diagnostics to patients from over 30 Shanghai area hospitals and conducting translational research on hematopoietic and lymphoid disorders in China.

For more information, please contact Dr. Richard Irons by calling Cinpathogen's Boulder, Colorado office (303-381-2543) or Shanghai office ( 86-21-5423-7760).

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Irons
Visit website